Compare Domino's Pizza, Inc. (DPZ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs ResMed Inc. — how do they compare? Domino's Pizza, Inc. trades at $354.24 (market cap $11.82B), while ResMed Inc. trades at $224.47 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.8× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals.
| DPZ | RMD | |
|---|---|---|
Market Cap | $11.82B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $293.73 |
52-Week Low | $282.89 | $182.82 |
Enterprise Value | $16.78B | $31.97B |
Dividend Yield | 2.23% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $347.85, down 0.88% on the day, with mixed technical signals showing neutral overall momentum. The company reported three consecutive quarterly EPS misses but maintains strong profitability with 11.86% net margins and positive revenue growth. Recent news highlights product innovation with the launch of individual-sized pizzas and digital platform enhancements to drive customer engagement.
Wall Street maintains a bullish stance with 54% buy ratings and a $371.67 price target, representing 7% upside potential. Key risks include elevated debt levels, competitive pressures, and consumer spending sensitivity. The stock offers value through consistent dividends and operational efficiency, though near-term execution on sales growth remains critical.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
